OCUP News and Press, Ocuphire Pharma Inc Com From 06/17/21

Processa Pharmaceuticals (PCSA) has entered into a licensing agreement with Ocuphire Pharma (OCUP), up 4% premarket to license in RX-3117.Processa will evaluate the potential benefit of RX-3117 for patients with pancreatic or non-small cell lung cancer. Under the terms of the agreem...

HANOVER, MD, June 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP) to license in RX-3117. RX-3117 is an oral, anticancer agent with an improved pharmacological ...

FARMINGTON HILLS, Mich., June 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on development and commercialization of therapies for the treatment of several eye disorders, today announced that the Company is se...

FARMINGTON HILLS, Mich., June 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on development and commercialization of therapies for the treatment of several eye disorders, announced today the closing of its pre...

FARMINGTON HILLS, Mich., June 08, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced the appointment of Jay S. Pe...

A clinical-stage ophthalmic biopharmaceutical company, Ocuphire Pharma (OCUP) enters into a securities purchase agreement with institutional investors for the purchase and sale of 3.07M shares and warrants to purchase 1.54M shares.It will be priced at a combined of $4.875 per one share a...

FARMINGTON HILLS, Mich., June 04, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced it has entered into a securi...

Highlights of Recent Positive Data from Nyxol’s Phase 3 Registration Trial Roundtable Discussion by 3 KOLs with Unique Perspectives and Distinct Patient Populations Webinar on Wednesday, May 26 th @ 1:00 pm EDT FARMINGTON HILLS, Mich., May 20, 20...

Stealth BioTherapeutics (MITO) +31% on Q1 results.Ultralife Corporation (ULBI) +22% on new contract from U.S. Army.China HGS Real Estate Inc. (HGSH) +14% on Q2 results.XpresSpa Group (XSPA) +9% on Q1 results.Reliance Global Group (RELI) +8%.Express (EXPR) +7%.Eloxx Pharmac...

The USPTO has issued two patents covering Ocuphire Pharma's (OCUP) late-stage product candidate, Nyxol (phentolamine mesylate).Both patents are directed to categories of subject matter eligible for listing in the U.S. FDA Orange Book:Nyxol for Treatment of Presbyopia: U.S. Patent No. 10,...